Lifestyle interventions have shown to reverse hyperglycemia to normoglycemia. However, most interventions are cost-intensive. Formula diets have shown to improve glycemic control and be cost-effective. We, therefore, hypothesized that adding a low-carbohydrate formula diet to a low-intense lifestyle intervention is superior in reversing prediabetes than lifestyle intervention alone. In this predefined subanalysis of a multicenter RCT (ACOORH study (no. NIHR CRN 3571)) including a total of n=463 obese subjects, overweight persons (n=141, BMI: >27 kg/m²) with prediabetes (defined as HbA1c: 5.7-6.4%) were randomized (1:2) into either a lifestyle intervention control group (CON, n=45) or a formula diet-based lifestyle intervention group (INT, n=96). Both groups were equipped with telemonitoring devices, received information on healthy diet and were instructed to increase physical activity. Additionally, INT received a low-carbohydrate, soy-protein-rich product (Almased®) substituting three meals/day (~1200 kcal) within the first week. During weeks 2-4, participants replaced two meals/day and during weeks 5-26 only one meal/day was substituted (1300-1500 kcal/day). Follow-up was performed after 52 weeks. Intention-to-treat analyses were performed. Nine and 8 persons of CON and INT (20% vs. 8%; P<0.05) dropped out after 12 weeks and 17 and 31 (38% vs. 32%, P=0.567) after 52 weeks. Compared to CON significantly more subjects in INT converted to normoglycemia after 52 weeks (51% vs. 32%; P<0.05). The risk reduction led to a number-needed-to-treat of 5.3 for INT. Concomitantly, INT reduced weight more significantly (-5.9 kg with 95% CI [-6.9; -4.9] vs. -2.4 kg [-4.0; -0.9]; P<0.001) after 12 weeks, while there was no difference after 52 weeks between groups. A low-intense lifestyle intervention with a low-carbohydrate formula diet reduces prediabetes prevalence stronger than a lifestyle intervention alone.


S. Martin: Consultant; Self; Almased Wellness GmbH, AstraZeneca, Lilly Diabetes. W. Banzer: None. A. Berg: Research Support; Self; Almased Wellness GmbH. K. Braumann: None. D. Fuhrer: Research Support; Self; Almased Wellness GmbH. M. Halle: Advisory Panel; Self; Merck Sharp & Dohme Corp. Research Support; Self; Novartis AG. Speaker's Bureau; Self; Amgen Inc., AstraZeneca, Berlin-Chemie AG, Daiichi Sankyo Company, Limited, Merck Sharp & Dohme Corp., Novartis AG, Pfizer Inc., Sanofi. D. McCarthy: None. M. Pinget: None. G. Predel: None. H. Toplak: Advisory Panel; Self; Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Merck Sharp & Dohme Corp., Mylan, Novartis AG, Novo Nordisk A/S, Sanofi. Research Support; Self; Amgen Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Novartis AG, Novo Nordisk A/S, Sanofi. Speaker's Bureau; Self; Amgen Inc., Amgen Inc., AstraZeneca, Bayer AG, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Merck Sharp & Dohme Corp., Mylan, Novo Nordisk Inc., Sanofi.


Almased Wellness GmbH

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at